Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver
Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) usi...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-05-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520312396 |
id |
doaj-7b48d2ba7b554bd8aaf864108108d737 |
---|---|
record_format |
Article |
spelling |
doaj-7b48d2ba7b554bd8aaf864108108d7372021-04-28T05:57:18ZengElsevierJournal of Lipid Research0022-22752015-05-015659981005Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liverShuichi Nagashima0Hiroaki Yagyu1Ryuichi Tozawa2Fumiko Tazoe3Manabu Takahashi4Tetsuya Kitamine5Daisuke Yamamuro6Kent Sakai7Motohiro Sekiya8Hiroaki Okazaki9Jun-ichi Osuga10Akira Honda11Shun Ishibashi12Division of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDepartment of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, JapanDivision of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, JapanJoint Research Center, Tokyo Medical University Ibaraki Medical Center, Ibaraki 300-0395, JapanTo whom correspondence should be addressed.; Division of Endocrinology and Metabolism, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan; To whom correspondence should be addressed.Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) using Cre-loxP technology. Hepatic SS activity of L-SSKO mice was reduced by >90%. In addition, cholesterol biosynthesis in the liver slices was almost eliminated. Although the hepatic squalene contents were markedly reduced in L-SSKO mice, the hepatic contents of cholesterol and its precursors distal to squalene were indistinguishable from those of control mice, indicating the presence of sufficient centripetal flow of cholesterol and/or its precursors from the extrahepatic tissues. L-SSKO mice showed a transient liver dysfunction with moderate hepatomegaly presumably secondary to increased farnesol production. In a fed state, the plasma total cholesterol and triglyceride were significantly reduced in L-SSKO mice, primarily owing to reduced hepatic VLDL secretion. In a fasted state, the hypolipidemic effect was lost. mRNA expression of liver X receptor α target genes was reduced, while that of sterol-regulatory element binding protein 2 target genes was increased. In conclusion, liver-specific ablation of SS inhibits hepatic cholesterol biosynthesis and induces hypolipidemia without increasing significant mortality.http://www.sciencedirect.com/science/article/pii/S0022227520312396cholesterol/biosynthesisenzymology/enzyme regulationlipoproteins/metabolismvery low density lipoproteininborn errors of metabolismCre recombinase |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shuichi Nagashima Hiroaki Yagyu Ryuichi Tozawa Fumiko Tazoe Manabu Takahashi Tetsuya Kitamine Daisuke Yamamuro Kent Sakai Motohiro Sekiya Hiroaki Okazaki Jun-ichi Osuga Akira Honda Shun Ishibashi |
spellingShingle |
Shuichi Nagashima Hiroaki Yagyu Ryuichi Tozawa Fumiko Tazoe Manabu Takahashi Tetsuya Kitamine Daisuke Yamamuro Kent Sakai Motohiro Sekiya Hiroaki Okazaki Jun-ichi Osuga Akira Honda Shun Ishibashi Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver Journal of Lipid Research cholesterol/biosynthesis enzymology/enzyme regulation lipoproteins/metabolism very low density lipoprotein inborn errors of metabolism Cre recombinase |
author_facet |
Shuichi Nagashima Hiroaki Yagyu Ryuichi Tozawa Fumiko Tazoe Manabu Takahashi Tetsuya Kitamine Daisuke Yamamuro Kent Sakai Motohiro Sekiya Hiroaki Okazaki Jun-ichi Osuga Akira Honda Shun Ishibashi |
author_sort |
Shuichi Nagashima |
title |
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
title_short |
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
title_full |
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
title_fullStr |
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
title_full_unstemmed |
Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
title_sort |
plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2015-05-01 |
description |
Squalene synthase (SS) catalyzes the biosynthesis of squalene, the first specific intermediate in the cholesterol biosynthetic pathway. To test the feasibility of lowering plasma cholesterol by inhibiting hepatic SS, we generated mice in which SS is specifically knocked out in the liver (L-SSKO) using Cre-loxP technology. Hepatic SS activity of L-SSKO mice was reduced by >90%. In addition, cholesterol biosynthesis in the liver slices was almost eliminated. Although the hepatic squalene contents were markedly reduced in L-SSKO mice, the hepatic contents of cholesterol and its precursors distal to squalene were indistinguishable from those of control mice, indicating the presence of sufficient centripetal flow of cholesterol and/or its precursors from the extrahepatic tissues. L-SSKO mice showed a transient liver dysfunction with moderate hepatomegaly presumably secondary to increased farnesol production. In a fed state, the plasma total cholesterol and triglyceride were significantly reduced in L-SSKO mice, primarily owing to reduced hepatic VLDL secretion. In a fasted state, the hypolipidemic effect was lost. mRNA expression of liver X receptor α target genes was reduced, while that of sterol-regulatory element binding protein 2 target genes was increased. In conclusion, liver-specific ablation of SS inhibits hepatic cholesterol biosynthesis and induces hypolipidemia without increasing significant mortality. |
topic |
cholesterol/biosynthesis enzymology/enzyme regulation lipoproteins/metabolism very low density lipoprotein inborn errors of metabolism Cre recombinase |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520312396 |
work_keys_str_mv |
AT shuichinagashima plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT hiroakiyagyu plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT ryuichitozawa plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT fumikotazoe plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT manabutakahashi plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT tetsuyakitamine plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT daisukeyamamuro plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT kentsakai plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT motohirosekiya plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT hiroakiokazaki plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT junichiosuga plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT akirahonda plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver AT shunishibashi plasmacholesterolloweringandtransientliverdysfunctioninmicelackingsqualenesynthaseintheliver |
_version_ |
1721504851501776896 |